Search results for "Agent"

showing 10 items of 8904 documents

Scoping the effectiveness and evolutionary obstacles in using plasmid-dependent phages to fight antibiotic resistance

2016

Aim: To investigate the potential evolutionary obstacles in the sustainable therapeutic use of plasmid-dependent phages to control the clinically important conjugative plasmid-mediated dissemination of antibiotic resistance genes to pathogenic bacteria. Materials & methods: The lytic plasmid-dependent phage PRD1 and the multiresistance conferring plasmid RP4 in an Escherichia coli host were utilized to assess the genetic and phenotypic changes induced by combined phage and antibiotic selection. Results & conclusions: Resistance to PRD1 was always coupled with either completely lost or greatly reduced conjugation ability. Reversion to full conjugation efficiency was found to be rare…

0301 basic medicineMicrobiology (medical)Phage therapymedicine.medical_treatment030106 microbiologyBiologymedicine.disease_causeMicrobiologyMicrobiology03 medical and health sciencesPlasmidAntibiotic resistanceDrug Resistance BacterialEscherichia colimedicineHumansBacteriophagesEscherichia coliEscherichia coli InfectionsGeneticsBacterial conjugationPathogenic bacteriaAnti-Bacterial AgentsLytic cycleConjugation GeneticHorizontal gene transferPlasmidsFuture Microbiology
researchProduct

Spread of Klebsiella pneumoniae ST395 non-susceptible to carbapenems and resistant to fluoroquinolones in North-Eastern France

2017

Abstract Objectives Fluoroquinolones (FQs) are a potential treatment for infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae that are susceptible to these agents. Methods Owing to increasing non-susceptibility to carbapenems among Enterobacteriaceae, in this study FQ resistance mechanisms were characterised in 36 ertapenem-non-susceptible Klebsiella pneumoniae isolated from North-Eastern France in 2012. The population structure was described by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Results Among the 36 isolates, 13 (36%) carried a carbapenemase encoding-gene. Decreased expression of the OmpK35-encoding gene might be…

0301 basic medicineMicrobiology (medical)QRDRCarbapenemST395Klebsiella pneumoniaeR Factors030106 microbiologyImmunologyMicrobial Sensitivity Tests[ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyMicrobiologybeta-LactamasesMicrobiologyPMQR03 medical and health scienceschemistry.chemical_compoundPlasmid[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyDrug Resistance Multiple BacterialmedicinePulsed-field gel electrophoresisHumansImmunology and AllergyCarbapenemComputingMilieux_MISCELLANEOUSbiologychlorhexidinebiology.organism_classificationmedicine.diseaseEnterobacteriaceaeVirology[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyAnti-Bacterial AgentsKlebsiella Infections3. Good healthKlebsiella pneumoniae[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyCarbapenemschemistryMultilocus sequence typingFranceKlebsiella pneumoniaErtapenemFluoroquinolonesMultilocus Sequence TypingPlasmidsmedicine.drugMLST
researchProduct

High vancomycin MICs within the susceptible range in Staphylococcus aureus bacteraemia isolates are associated with increased cell wall thickness and…

2016

Vancomycin minimum inhibitory concentrations (MICs) at the upper end of the susceptible range for Staphylococcus aureus have been associated with poor clinical outcomes of bloodstream infections. We tested the hypothesis that high vancomycin MICs in S. aureus bacteraemia isolates are associated with increased cell wall thickness and suboptimal bacterial internalisation or lysis by human phagocytes. In total, 95 isolates were evaluated. Original vancomycin MICs were determined by Etest. The susceptibility of S. aureus isolates to killing by phagocytes was assessed in a human whole blood assay. Internalisation of bacterial cells by phagocytes was investigated by flow cytometry. Cell wall thic…

0301 basic medicineMicrobiology (medical)Staphylococcus aureusLysisGenotyping Techniques030106 microbiologyBacteremiaMicrobial Sensitivity TestsBiologymedicine.disease_causeStaphylococcal infectionsMicrobiologyFlow cytometry03 medical and health sciences0302 clinical medicineCell WallVancomycinmedicineHumansPharmacology (medical)030212 general & internal medicineMinimum inhibitory concentration (MIC)EtestPhagocytesCell wall thicknessMicrobial Viabilitymedicine.diagnostic_testGeneral MedicineHuman phagocytesStaphylococcal InfectionsFlow CytometryMicroarray Analysismedicine.diseaseEndocytosisAnti-Bacterial AgentsIntracellular killingInfectious DiseasesStaphylococcus aureusBacteremiaVancomycinIntracellularmedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs.

2019

International audience; BACKGROUND:Infections with antibiotic-resistant pathogens in cancer patients are a leading cause of mortality. Cancer patients are treated with compounds that can damage bacterial DNA, potentially triggering the SOS response, which in turn enhances the bacterial mutation rate. Antibiotic resistance readily occurs after mutation of bacterial core genes. Thus, we tested whether cancer chemotherapy drugs enhance the emergence of resistant mutants in commensal bacteria.METHODS:Induction of the SOS response was tested after the incubation of Escherichia coli biosensors with 39 chemotherapeutic drugs at therapeutic concentrations. The mutation frequency was assessed after …

0301 basic medicineMicrobiology (medical)Staphylococcus aureusmedicine.drug_class030106 microbiologyAntibioticsAntineoplastic AgentsDrug resistanceMicrobial Sensitivity TestsBiologymedicine.disease_causeMicrobiology03 medical and health sciencesSOS Response (Genetics)0302 clinical medicineAntibiotic resistanceDrug Resistance BacterialEnterobacter cloacaemedicineHumansPharmacology (medical)030212 general & internal medicineMutation frequencySOS responseSOS Response GeneticsPharmacologyPathogenic bacteriaChemotherapy regimen3. Good healthAnti-Bacterial Agents[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesPseudomonas aeruginosaThe Journal of antimicrobial chemotherapy
researchProduct

Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomo…

2021

AbstractObjectivesTo assess performance of disc diffusion, gradient tests and Vitek 2 system to determine the susceptibility of clinical Pseudomonas aeruginosa strains to ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA).MethodsTwo-hundred non-duplicate P. aeruginosa strains isolated by 47 French medical laboratories were selected to cover a wide range of C/T and CZA MICs. Performance of C/T disc (30/10 μg, Bio-Rad), CZA discs (10/4 μg) (Thermo Fisher and Bio-Rad), C/T and CZA gradient tests (Etest, BioMérieux; MIC Test Strip, Liofilchem), and AST-XN12 card of Vitek 2 system (BioMérieux) were compared with a broth microdilution (BMD) method (Thermo Fisher). MIC and disc results w…

0301 basic medicineMicrobiology (medical)TazobactamAvibactam030106 microbiologyCeftazidimeMicrobial Sensitivity Testsmedicine.disease_causeTazobactamCeftazidime03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansPharmacology (medical)Pseudomonas Infections030212 general & internal medicineEtestPharmacologyChromatographyPseudomonas aeruginosaChemistryBroth microdilutionCeftazidime/avibactamAnti-Bacterial AgentsCephalosporinsDrug CombinationsInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyPseudomonas aeruginosaCeftolozaneAzabicyclo Compoundsmedicine.drug
researchProduct

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

2017

International audience; Background: Moxifloxacin retains partial activity against some fluoroquinolone-resistant mutants of Mycobacterium tuberculosis. Levofloxacin is presumed to be as active as moxifloxacin against drug-susceptible tuberculosis and to have a better safety profile.Objectives: To compare the in vivo activity of levofloxacin and moxifloxacin against M. tuberculosis strains with various levels of fluoroquinolone resistance.Methods: BALB/c mice were intravenously infected with 106M. tuberculosis H37Rv and three isogenic mutants: GyrA A90V, GyrB E540A and GyrB A543V. Treatment with 50 or 100 mg/kg levofloxacin and 60 or 66 mg/kg moxifloxacin was given orally every 6 h, for 4 we…

0301 basic medicineMicrobiology (medical)Tuberculosis[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationmiceExtensively Drug-Resistant Tuberculosis030106 microbiologyMicrobial Sensitivity TestsMicrobiologyMycobacterium tuberculosis03 medical and health sciences0302 clinical medicine[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationLevofloxacinMoxifloxacinIn vivo[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesmedicineAnimalsPharmacology (medical)heterocyclic compounds030212 general & internal medicinePharmacologyMice Inbred BALB ClevofloxacinbiologyChemistry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationExtensively drug-resistant tuberculosisMycobacterium tuberculosisbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationbacterial infections and mycosesFluoroquinolone resistanceAnti-Bacterial Agents3. Good health[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesDisease Models AnimalSafety profileTreatment OutcomeInfectious Diseasestuberculosis[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesbacteriamoxifloxacinFluoroquinolonesmedicine.drug
researchProduct

Resistance to third-generation cephalosporins in Escherichia coli in the French community: The times they are a-changin'?

2020

Since the early 2000s, Escherichia coli resistance to third-generation cephalosporins (3GCs) has been increasing in all European countries, mainly due to the spread of extended spectrum β-lactamases (ESBLs). Here we present a retrospective study that combines resistance of E. coli to 3GCs and quinolones with data on antibiotic use in the community in a region of Northeastern France.Since 2012, an observational surveillance of antimicrobial resistance and antibiotic use in the community was conducted: data on antimicrobial resistance in E. coli isolates were collected from 11 private laboratories, and consumption data were collected from the three main healthcare insurances.A significant dec…

0301 basic medicineMicrobiology (medical)Veterinary medicinemedicine.drug_classeducationResistance030106 microbiologyCephalosporinAntibioticsContext (language use)Microbial Sensitivity TestsQuinolonesmedicine.disease_causebeta-LactamasesThird generation cephalosporins03 medical and health sciencesNalidixic Acid0302 clinical medicineAntibiotic resistanceCiprofloxacinDrug Resistance BacterialOutpatientsmedicineEscherichia coliPrevalenceHumansPharmacology (medical)030212 general & internal medicineAntibiotic useEscherichia coliComputingMilieux_MISCELLANEOUSEscherichia coli InfectionsRetrospective StudiesResistance (ecology)business.industryThird-generation cephalosporinsGeneral Medicine3. Good healthAnti-Bacterial AgentsCephalosporins[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious Diseases[SDE]Environmental SciencesFrancebusinessInternational journal of antimicrobial agents
researchProduct

Genotyping Reveals High Clonal Diversity and Widespread Genotypes of Candida Causing Candidemia at Distant Geographical Areas

2020

The objectives of this study were to gain further insight on Candida genotype distribution and percentage of clustered isolates between hospitals and to identify potential clusters involving different hospitals and cities. We aim to genotype Candida spp. isolates causing candidemia in patients admitted to 16 hospitals in Spain, Italy, Denmark, and Brazil. Eight hundred and eighty-four isolates (Candida albicans, n = 534; C. parapsilosis, n = 282; and C. tropicalis, n = 68) were genotyped using species-specific microsatellite markers. CDC3, EF3, HIS3, CAI, CAIII, and CAVI were used for C. albicans, Ctrm1, Ctrm10, Ctrm12, Ctrm21, Ctrm24, and Ctrm28 for C. tropicalis, and CP1, CP4a, CP6, and B…

0301 basic medicineMicrobiology (medical)Veterinary medicinemicrosatelliteAntifungal AgentsGenotype030106 microbiologyImmunologylcsh:QR1-502Microbiologylcsh:MicrobiologySettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA03 medical and health sciencesCellular and Infection MicrobiologyGenotypewidespreadHumansTypingCandida albicansclusterGenotypingOriginal ResearchClonal diversityCandidaGenetic diversitybiologyCandidemiabiology.organism_classificationCorpus albicans030104 developmental biologyInfectious DiseasesItalygenotypingSpainMicrosatelliteBrazilFrontiers in Cellular and Infection Microbiology
researchProduct

Evaluation of five automated and one manual method for Toxoplasma and human DNA extraction from artificially spiked amniotic fluid.

2018

International audience; Objectives - Molecular detection of Toxoplasma gondii plays a crucial role in the prenatal and neonatal diagnosis of congenital toxoplasmosis (CT). Sensitivity of this diagnosis is partly related to the efficiency of parasite DNA extraction and amplification. DNA extraction methods with automated platforms have been developed. Therefore, it is essential to evaluate them in combination with adequate PCR amplification assays.Methods - In this multisite study, we investigated the suitability of two recent automated procedures for the isolation of Toxoplasma DNA from amniotic fluid (AF) (Magtration system 12GC, PSS and Freedom EVO VacS, Tecan), compared with three other …

0301 basic medicineMicrobiology (medical)[ SDV.MP.PAR ] Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyAmniotic fluid030106 microbiologyToxoplasma gondiiPolymerase Chain ReactionSensitivity and SpecificityToxoplasmosis Congenitallaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelawparasitic diseasesDiagnosisTaqManHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology030212 general & internal medicineDNA extractionPolymerase chain reactionChromatographyCongenital toxoplasmosisbiologyExtraction (chemistry)Toxoplasma gondiiNucleic Acid Hybridization[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieGeneral Medicinerep529DNADNA Protozoanbiology.organism_classificationAmniotic FluidDNA extractionCongenital toxoplasmosisrap5293. Good healthInfectious DiseasesPCRchemistry[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieBiological AssayReagent Kits DiagnosticToxoplasmaDNAClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct

Antiviral Agents From Fungi : Diversity, Mechanisms and Potential Applications

2018

Viral infections are amongst the most common diseases affecting people worldwide. New viruses emerge all the time and presently we have limited number of vaccines and only few antivirals to combat viral diseases. Fungi represent a vast source of bioactive molecules, which could potentially be used as antivirals in the future. Here, we have summarized the current knowledge of fungi as producers of antiviral compounds and discuss their potential applications. In particular, we have investigated how the antiviral action has been assessed and what is known about the molecular mechanisms and actual targets. Furthermore, we highlight the importance of accurate fungal species identification on ant…

0301 basic medicineMicrobiology (medical)endofyytitnatural productsBioactive moleculesmedia_common.quotation_subjectantiviral mechanismslcsh:QR1-502fungal secondary metabolitesendophytesluonnontuotteetReviewComputational biologyBiology01 natural sciencesMicrobiologylcsh:Microbiology03 medical and health sciencesantiviral agentsSpecies identificationpuolustusmekanismit (biologia)media_commonantimikrobiset yhdisteet010405 organic chemistrymedicinal mushroomsta1183ta1182luonnonaineet0104 chemical sciences030104 developmental biologyvirustauditsienetDiversity (politics)
researchProduct